A 10-year perspective on donepezil

Bibliography

• Perry EK, Tomlinson BE, Blessed G, Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2(6150):1457-9
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Price DL, Clark AW, Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 1981;10(2):122-6
   PubMed Web of Science ®Google Scholar
• Drachman DA, Glosser G, Fleming P, Memory decline in the aged Treatment with lecithin and physostigmine. Neurology 1982;32(9):944
   PubMed Web of Science ®Google Scholar
• Summers WK, Majovski LV, Marsh GM, Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986;315(20):1241-5
   PubMed Web of Science ®Google Scholar
• Rogers S, Friedhoff L. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dement Geriatr Cogn Disord 1996;7(6):293-303
   Google Scholar
• Rogers S, Farlow M, Doody R, A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50(1):136-45
   PubMed Web of Science ®Google Scholar
• Mihara M, Ohnishi A, Tomono Y, Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmaco. Ther Toxicol 1993;31(5):223
   Google Scholar
• Tiseo P, Foley K, Friedhoff L. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clinl Pharmacol 1998;46(S1):35
   Google Scholar
• Tiseo P, Foley K, Friedhoff L. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46(S1):45
   Google Scholar
• Tiseo P, Perdomo C, Friedhoff L. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(S1):25
   Google Scholar
• Tiseo P, Perdomo C, Friedhoff L. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Clin Pharmacol 1998;46(S1):40
   Google Scholar
• Tiseo P, Perdomo C, Friedhoff L. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998;46(S1):30
   Google Scholar
• Rogers S, Walters E, Friedhoff L. The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 ((R, S)-1-benzyl-4-((5, 6-dimethoxy-1-indanon)-2-yl)-methylpiperidine hydrochloride), a novel inhibitor of acetylcholinesterase (AChE): implications for use in Alzheimer's disease. Neurobiol Aging 1992;13(Suppl 1):S125-S6
   Google Scholar
• Tiseo P, Foley K, Friedhoff L. An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. British Journal of Clinical Pharmacology 1998;46(S1):56
   Google Scholar
• Petersen RC, Thomas RG, Grundman M, Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005;352(23):2379-88
   PubMed Web of Science ®Google Scholar
• Salloway S, Ferris S, Kluger A, Efficacy of donepezil in mild cognitive impairment A randomized placebo-controlled trial. Neurology 2004;63(4):651-7
   PubMed Web of Science ®Google Scholar
• Burns A, Rossor M, Hecker J, The Effects of Donepezil in Alzheimer's Disease–Results from a Multinational Trial1. Dement Geriatr Cogn Disord 1999;10(3):237-44
   PubMed Web of Science ®Google Scholar
• Homma A, Takeda M, Imai Y, Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11(6):299-313
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H, A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57(3):489-95
   PubMed Web of Science ®Google Scholar
• Mohs RC, Doody R, Morris J, A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57(3):481-8
   PubMed Web of Science ®Google Scholar
• Rogers S, Doody R, Pratt R, Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000;10(3):195-203
   PubMed Web of Science ®Google Scholar
• Gauthier S, Feldman H, Hecker J, Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr 2002;14(4):389-404
   Google Scholar
• Feldman H, Gauthier S, Hecker J, A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57(4):613-20
   PubMed Web of Science ®Google Scholar
• Winblad B, Kilander L, Eriksson S. Donepezil in patients with severe Alzheimer's disease. Lancet 2006;367:1057-65
   PubMed Web of Science ®Google Scholar
• Farlow MR, Salloway S, Tariot PN, Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010;32(7):1234-51
   PubMed Web of Science ®Google Scholar
• Black S, Roman GC, Geldmacher DS, Efficacy and tolerability of donepezil in vascular dementia positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34(10):2323-30
   PubMed Web of Science ®Google Scholar
• Malouf R, Birks J. Evidence of efficacy of donepezil for people with mild or moderate vascular cognitive impairment. 2009
   Google Scholar
• Kaufer DI, Catt KE, Lopez OL, Dementia with Lewy bodies Response of delirium-like features to donepezil. Neurology 1998;51(5):1512
   PubMed Web of Science ®Google Scholar
• Aarsland D, Brønnick K, Karlsen K. Donepezil for dementia with Lewy bodies: a case study. Int J Geriatr Psychiatry 1999;14(1):69-72
   PubMed Web of Science ®Google Scholar
• Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: A randomized, placebo‐controlled trial. Ann Neurol 2012;72(1):41-52
   PubMed Web of Science ®Google Scholar
• Dubois B, Tolosa E, Katzenschlager R, Donepezil in Parkinson's disease dementia: A randomized, double‐blind efficacy and safety study. Mov Disord 2012;27(10):1230-8
   PubMed Web of Science ®Google Scholar
• Aarsland D, Laake K, Larsen J, Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72(6):708-12
   PubMed Web of Science ®Google Scholar
• Ravina B, Putt M, Siderowf A, Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76(7):934-9
   Google Scholar
• Geldmacher DS, Provenzano G, McRae T, Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003;51(7):937-44
   PubMed Web of Science ®Google Scholar
• O'Brien BJ, Goeree R, Hux M, Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc 1999;47(5):570
   Google Scholar
• Gauthier S, Patterson C, Chertkow H, 4th Canadian consensus conference on the diagnosis and treatment of dementia. Can J Neurol Sci 2012;39(Suppl 5):6
   Google Scholar
• Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003;18(4):282-4
   PubMed Web of Science ®Google Scholar